Vanguard Group’s Oxford Immunotec Global PLC Ordinary Shares OXFD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-70,220
| Closed | -$1.23M | – | 4353 |
|
|
2020
Q4 | $1.23M | Buy |
70,220
+5,047
| +8% | +$70.8K | ﹤0.01% | 3781 |
|
|
2020
Q3 | $763K | Buy |
65,173
+125
| +0.2% | +$1.66K | ﹤0.01% | 3721 |
|
|
2020
Q2 | $846K | Buy |
+65,048
| New | +$781K | ﹤0.01% | 3648 |
|
|
2019
Q2 | – | Sell |
-96,705
| Closed | -$1.67M | – | 4192 |
|
|
2019
Q1 | $1.67M | Buy |
96,705
+2,403
| +3% | +$38K | ﹤0.01% | 3507 |
|
|
2018
Q4 | $1.21M | Sell |
94,302
-1,345
| -1% | -$20.4K | ﹤0.01% | 3510 |
|
|
2018
Q3 | $1.55M | Buy |
95,647
+1,839
| +2% | +$26.3K | ﹤0.01% | 3607 |
|
|
2018
Q2 | $1.21M | Buy |
93,808
+10,801
| +13% | +$146K | ﹤0.01% | 3637 |
|
|
2018
Q1 | $1.03M | Buy |
83,007
+3,415
| +4% | +$41.6K | ﹤0.01% | 3640 |
|
|
2017
Q4 | $1.11M | Buy |
79,592
+9,567
| +14% | +$140K | ﹤0.01% | 3590 |
|
|
2017
Q3 | $1.18M | Buy |
70,025
+982
| +1% | +$16K | ﹤0.01% | 3548 |
|
|
2017
Q2 | $1.16M | Buy |
69,043
+3,507
| +5% | +$52.4K | ﹤0.01% | 3534 |
|
|
2017
Q1 | $1.01M | Buy |
65,536
+1,238
| +2% | +$17.7K | ﹤0.01% | 3576 |
|
|
2016
Q4 | $961K | Buy |
64,298
+4,081
| +7% | +$57.3K | ﹤0.01% | 3568 |
|
|
2016
Q3 | $756K | Buy |
60,217
+1,725
| +3% | +$17.3K | ﹤0.01% | 3648 |
|
|
2016
Q2 | $526K | Buy |
58,492
+4,041
| +7% | +$39.6K | ﹤0.01% | 3778 |
|
|
2016
Q1 | $540K | Sell |
54,451
-1,816
| -3% | -$18.6K | ﹤0.01% | 3776 |
|
|
2015
Q4 | $647K | Buy |
56,267
+1,046
| +2% | +$12.9K | ﹤0.01% | 3761 |
|
|
2015
Q3 | $746K | Buy |
55,221
+20,972
| +61% | +$284K | ﹤0.01% | 3726 |
|
|
2015
Q2 | $474K | Buy |
34,249
+7,276
| +27% | +$98.4K | ﹤0.01% | 3878 |
|
|
2015
Q1 | $380K | Buy |
26,973
+6,206
| +30% | +$84.5K | ﹤0.01% | 3890 |
|
|
2014
Q4 | $283K | Buy |
20,767
+492
| +2% | +$6.72K | ﹤0.01% | 3843 |
|
|
2014
Q3 | $310K | Sell |
20,275
-665
| -3% | -$10.2K | ﹤0.01% | 3823 |
|
|
2014
Q2 | $353K | Buy |
20,940
+10,826
| +107% | +$195K | ﹤0.01% | 3756 |
|
|
2014
Q1 | $203K | Buy |
+10,114
| New | +$219K | ﹤0.01% | 3818 |
|
Vanguard Group's OXFD Position: Q1 2021 in Review
Vanguard Group sold out of Oxford Immunotec Global PLC Ordinary Shares (OXFD) in Q1 2021, closing a stake of 70,220 shares — an estimated $1.23M sold.
Vanguard Group first reported a position in OXFD in Q1 2014 and held it in 24 quarters. The position peaked at $1.67M in Q1 2019. 0 funds tracked by Wall St. Rank hold OXFD as of Q1 2021.
- Vanguard Group reported no remaining Oxford Immunotec Global PLC Ordinary Shares position as of Q1 2021 after selling out during the quarter.
- Vanguard Group sold 70,220 Oxford Immunotec Global PLC Ordinary Shares shares in Q1 2021, an estimated $1.23M.
- Vanguard Group first reported a position in Oxford Immunotec Global PLC Ordinary Shares in Q1 2014 and held it in 24 quarters.
- Vanguard Group's Oxford Immunotec Global PLC Ordinary Shares position peaked at $1.67M in Q1 2019.
- 0 funds tracked by Wall St. Rank held Oxford Immunotec Global PLC Ordinary Shares as of Q1 2021.
Based on Vanguard Group's 13F filing for Q1 2021, filed 14 May 2021.